Last reviewed · How we verify
TTYP01, 120 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TTYP01, 120 mg (TTYP01, 120 mg) — Shanghai Auzone Biological Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TTYP01, 120 mg TARGET | TTYP01, 120 mg | Shanghai Auzone Biological Technology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TTYP01, 120 mg CI watch — RSS
- TTYP01, 120 mg CI watch — Atom
- TTYP01, 120 mg CI watch — JSON
- TTYP01, 120 mg alone — RSS
Cite this brief
Drug Landscape (2026). TTYP01, 120 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ttyp01-120-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing